NVOS — Novo Integrated Sciences Share Price
- $12.67m
- $15.01m
- $12.57m
- 30
- 69
- 14
- 31
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.7 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.14 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -37.54% | ||
Return on Equity | -48.89% | ||
Operating Margin | -68.69% |
Financial Summary
Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 9.42 | 7.86 | 9.31 | 11.74 | 12.57 | n/a | n/a | 7.17% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Novo Integrated Sciences, Inc. is a parent company to its subsidiaries. The Company owns Canadian and United States subsidiaries that provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutic, diagnostic solutions, personalized product offerings, and rehabilitative science. The Company operates through two segments: Healthcare Services and Product Sales. Its specialized multidisciplinary primary healthcare services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, dietician and others. Its subsidiaries include Novo Healthnet Limited, Novomerica Health Group, Inc., PRO-DIP, LLC and others.
Directors
- Robert Mattacchione CHM (53)
- Christopher David PRE (62)
- James Zsebok CFO (55)
- Michael Gaynor SEC (55)
- Pierre Dalcourt DRC (51)
- Alex Flesias IND (47)
- Robert Oliva IND (58)
- Michael Pope IND (41)
- Last Annual
- August 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- February 20th, 2008
- Public Since
- July 12th, 2005
- No. of Shareholders
- 527
- No. of Employees
- 127
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 19,054,523
- Address
- 11120 NE 2ND STREET, SUITE 100, BELLEVUE, 98004
- Web
- https://www.novointegrated.com/
- Phone
- +1 2066179797
- Contact
- Christopher David
- Auditors
- Fruci & Associates II,PLLC
Upcoming Events for NVOS
Novo Integrated Sciences Inc Annual Shareholders Meeting
Q4 2024 Novo Integrated Sciences Inc Earnings Release
Similar to NVOS
23andMe Holding Co.
NASDAQ Capital Market
ADVANCED BIOMED
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Assure Holdings
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
FAQ
As of Today at 16:25 UTC, shares in Novo Integrated Sciences are trading at $0.82. This share price information is delayed by 15 minutes.
Shares in Novo Integrated Sciences last closed at $0.82 and the price had moved by -44.93% over the past 365 days. In terms of relative price strength the Novo Integrated Sciences share price has underperformed the S&P500 Index by -56.18% over the past year.
There is no consensus recommendation for this security.
Novo Integrated Sciences does not currently pay a dividend.
Novo Integrated Sciences does not currently pay a dividend.
Novo Integrated Sciences does not currently pay a dividend.
To buy shares in Novo Integrated Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.82, shares in Novo Integrated Sciences had a market capitalisation of $15.62m.
Here are the trading details for Novo Integrated Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NVOS
Based on an overall assessment of its quality, value and momentum Novo Integrated Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novo Integrated Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -35.45%.
As of the last closing price of $0.82, shares in Novo Integrated Sciences were trading -36.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novo Integrated Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novo Integrated Sciences' management team is headed by:
- Robert Mattacchione - CHM
- Christopher David - PRE
- James Zsebok - CFO
- Michael Gaynor - SEC
- Pierre Dalcourt - DRC
- Alex Flesias - IND
- Robert Oliva - IND
- Michael Pope - IND